ArticleIndian pediatrics2026
Nirsevimab Implementation and Primary Management of Lower Respiratory Tract Infections in Infants in Spain: A Quasi-Experimental Study.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges in Evaluating Nirsevimab Effectiveness Across Pre- and Post-Pandemic Settings.Indian pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLower respiratory tract infections (LRTIs) are a common cause of primary care visits in infants. This study was done to evaluate the course of LRTIs before-and-after the introduction of nirsevimab and to identify the associated risk factors.
methodsThis was a quasi-experimental, before-and-after study, comparing two cohorts of infants followed during their first year of life, before (April-December 2017-2018) and after (April-December 2023-2024) following the introduction of nirsevimab. Clinical, epidemiological, and healthcare-related variables were analyzed.
resultsA total of 729 infants were included (n = 327 in 2017-2018; n = 402 in 2023-2024); 91.0% of infants in the second period received nirsevimab. The overall incidence of LRTIs did not differ between the two periods (26.3% vs. 23.9%; P = 0.453). Following the introduction of nirsevimab, diagnoses and follow-up in primary care increased (+ 35.3% and + 28.4%, respectively; both P < 0.001). No differences were observed in clinical severity (P = 0.301), emergency department referrals (P = 1.000), pharmacological treatment (P = 0.791), recurrences (P = 0.110), or hospitalizations (P = 1.000). In multivariable analysis, LRTI occurrence was independently associated with male sex, daycare attendance, school-aged siblings, passive smoking exposure, and lack of nirsevimab immunoprophylaxis.
conclusionsThe introduction of nirsevimab did not affect the severity of LRTI and was accompanied by a greater proportion of cases managed in primary care.
Indexed as
Identifiers
42319655What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.